Bone Morphogenetic Protein (BMP) signaling is a highly conserved cascade that is involved in many essential biological events across metazoans, like cell migration, proliferation, and differentiation. Numerous hereditary disorders ranging from cancer to cardiovascular disease can arise in humans when this pathway malfunctions. Consequently, gaining a better understanding of how this pathway is tightly regulated could help us to address and, ultimately, treat these medical conditions. In C. elegans, the BMP pathway is known to regulate body size, postembryonic mesoderm development, and several other developmental processes. Multiple factors have been identified to be involved in modulating BMP signaling. One such factor is the ADAM (a disintegrin and metalloprotease) protease SUP-17, whose mammalian ortholog is ADAM10. SUP-17/ADAM10 is a single-pass transmembrane protein that plays a fundamental role in ectodomain shedding, a post-translational modification where either a transmembrane or membrane-associated protein is cleaved at the extracellular domain through juxta-membrane processing. Our research aims to elucidate the role of SUP-17/ADAM10 by identifying its substrate(s) in BMP signaling. Towards this goal, we have used the CRISPR/Cas9 technique to tag multiple known transmembrane and membrane-associated proteins involved in BMP signaling with GFP and FLAG. We are conducting western blot analyses on wild-type and
sup-17 mutant worms carrying each of these tagged proteins. We also plan to use an unbiased proteomic approach to identify SUP-17/ADAM10 substrate(s) in BMP signaling. Results from these studies will shed light on how SUP-17/ADAM10 functions to regulate BMP signaling.